Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Orthopaedics
Published in: International Orthopaedics 4/2013

01-04-2013 | Original Paper

Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?

Authors: Jaap J. Brunnekreef, Paul Hoogervorst, Marieke J. Ploegmakers, Wim H. Rijnen, Berend W. Schreurs

Published in: International Orthopaedics | Issue 4/2013

Login to get access

Abstract

Purpose

Heterotopic ossification is a common complication after total hip arthroplasty. Non-steroidal anti-inflammatory drugs (NSAIDs) are known to prevent heterotopic ossifications effectively, however gastrointestinal complaints are reported frequently. In this study, we investigated whether etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor that produces fewer gastrointestinal side effects, is an effective alternative for the prevention of heterotopic ossification.

Methods

We investigated the effectiveness of oral etoricoxib 90 mg for seven days in a prospective two-stage study design for phase-2 clinical trials in a small sample of patients (n = 42). A cemented primary total hip arthroplasty was implanted for osteoarthritis. Six months after surgery, heterotopic ossification was determined on anteroposterior pelvic radiographs using the Brooker classification.

Results

No heterotopic ossification was found in 62 % of the patients that took etoricoxib; 31 % of the patients had Brooker grade 1 and 7 % Brooker grade 2 ossification.

Conclusions

Etoricoxib seems effective in preventing heterotopic ossification after total hip arthroplasty. This finding further supports the use of COX-2 inhibitors for the prevention of heterotopic ossification following total hip arthroplasty.
Literature
1.
Neal B, Gray H, MacMahon S, Dunn L (2002) Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg 72(11):808–821PubMedCrossRef
2.
Coventry MB, Scanlon PW (1981) The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. J Bone Joint Surg Am 63(2):201–208PubMed
3.
Fransen M, Neal B (2004) Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 3:CD001160PubMed
4.
Neal BC, Rodgers A, Clark T, Gray H, Reid IR, Dunn L, MacMahon SW (2000) A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 71(2):122–128PubMedCrossRef
5.
Balboni TA, Gobezie R, Mamon HJ (2006) Heterotopic ossification: Pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. Int J Radiat Oncol Biol Phys 65(5):1289–1299PubMedCrossRef
6.
Blokhuis TJ, Frolke JP (2009) Is radiation superior to indomethacin to prevent heterotopic ossification in acetabular fractures?: a systematic review. Clin Orthop Relat Res 467(2):526–530PubMedCrossRef
7.
Burd TA, Hughes MS, Anglen JO (2003) Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 85(5):700–705PubMed
8.
Cella JP, Salvati EA, Sculco TP (1988) Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty 3(3):229–234PubMedCrossRef
9.
Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98(8):1725–1733PubMedCrossRef
10.
Xue D, Zheng Q, Li H, Qian S, Zhang B, Pan Z (2009) Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials. Int Orthop 35(1):3–8PubMedCrossRef
11.
Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr (1973) Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 55(8):1629–1632PubMed
12.
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10PubMedCrossRef
13.
van der Heide HJ, Koorevaar RC, Lemmens JA, van Kampen A, Schreurs BW (2007) Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 127(7):557–561PubMedCrossRef
14.
van der Heide HJ, Rijnberg WJ, Van Sorge A, Van Kampen A, Schreurs BW (2007) Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop 78(1):90–94PubMedCrossRef
15.
van der Heide HJ, Koorevaar RT, Schreurs BW, van Kampen A, Lemmens A (1999) Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty 14(7):796–799PubMedCrossRef
16.
Renner B, Walter G, Strauss J, Fromm MF, Zacher J, Brune K (2012) Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief. Eur J Pain 16(6):838–848PubMedCrossRef
17.
Macfarlane RJ, Ng BH, Gamie Z, El Masry MA, Velonis S, Schizas C, Tsiridis E (2008) Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother 9(5):767–786PubMedCrossRef
18.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102PubMedCrossRef
19.
Weir MR, Sperling RS, Reicin A, Gertz BJ (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146(4):591–604PubMedCrossRef
20.
Weber EW, Slappendel R, Durieux ME, Dirksen R, van der Heide H, Spruit M (2003) COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 20(12):963–966PubMedCrossRef
Metadata
Title
Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?
Authors
Jaap J. Brunnekreef
Paul Hoogervorst
Marieke J. Ploegmakers
Wim H. Rijnen
Berend W. Schreurs
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
International Orthopaedics / Issue 4/2013
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI
https://doi.org/10.1007/s00264-013-1781-0

Other articles of this Issue 4/2013

International Orthopaedics 4/2013 Go to the issue

Original Paper

The First SICOT Oral Presentation Award 2011: Imageless computer-assisted femoral component positioning in hip resurfacing: a prospective randomised trial

Original Paper

Prevascularisation with endothelial progenitor cells improved restoration of the architectural and functional properties of newly formed bone for bone reconstruction

Review Article

Total joint replacement and blood loss: what is the best equation?

Original Paper

Ilizarov non-free bone plasty for extensive tibial defects

Original Paper

Bilateral scapular fractures in adults

Original Paper

Ten year results of transtrochanteric valgus osteotomy with or without the shelf procedure